ABVC BioPharma, Inc entered into a securities purchase agreement with Lind Global Fund II, LP for a private placement of secured convertible note for gross proceeds of $1,000,000 on November 17, 2023. The note carries a principal amount of $1,200,000.The note will be issued at an original issue discount of approximately 16.67%.The notes are convertible into shares of the Company?s common stock at a conversion price, which shall be the lesser of (i) $3.50 (the ? Fixed Price ?) and (ii) 90% of the three lowest VWAPs (as defined in the Note) during the 20 trading days prior to conversion.

The company has also issued the investor 5-year, common stock purchase warrant (the ? Warrant ?) to purchase up to 1,000,000 shares of the Company?s common stock at an initial exercise price of $2 per share, subject to adjustment.